From 10Q filed 5.17.11
Over the next 12 months we anticipate that we will require an aggregate of $700,000 in cash and stock-based compensation to cover expenses and debt service, including certain accounts payable, as follows
a)
$50,000 for facility and equipment related expenses;
(b)
$60,000 for debt service;
(c)
$120,000 for pre-clinical work, quality assurance, manufacturing of biologic material, academic collaborations and further research collaborations;
(d)
$80,000 for design and device manufacturing;
(e)
$150,000 for legal expenses related to general corporate matters, and accounting expenses related to quarterly reviews and annual audits;
(f)
$125,000 for salaries and consulting; and
(g)
$115,000 for general and administrative, travel, conferences and public relations.
My opinions should not be construed as investment advice.
